{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:48:33Z","timestamp":1787003313498,"version":"build-2736575974"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cannabis use disorder (CUD) occurs at high rates in schizophrenia, which negatively impacts its clinical prognosis. These patients have greater difficulty quitting cannabis which may reflect putative deficits in the dorsolateral prefrontal cortex (DLPFC), a potential target for treatment development. We examined the effects of active versus sham high-frequency (20-Hz) repetitive transcranial magnetic stimulation (rTMS) on cannabis use in outpatients with schizophrenia and CUD. Secondary outcomes included cannabis craving\/withdrawal, psychiatric symptoms, cognition and tobacco use. Twenty-four outpatients with schizophrenia and CUD were enrolled in a preliminary double-blind, sham-controlled randomized trial. Nineteen participants were randomized to receive active (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20099) or sham (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910) rTMS (20-Hz) applied bilaterally to the DLPFC 5x\/week for 4 weeks. Cannabis use was monitored twice weekly. A cognitive battery was administered pre- and post-treatment. rTMS was safe and well-tolerated with high treatment retention (~90%). Contrast estimates suggested greater reduction in self-reported cannabis use (measured in grams\/day) in the active versus sham group (Estimate\u2009=\u20090.33,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.21; Cohen\u2019s\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u20090.72), suggesting a clinically relevant effect of rTMS. A trend toward greater reduction in craving (Estimate\u2009=\u20093.92,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.06), and significant reductions in PANSS positive (Estimate\u2009=\u20092.42,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02) and total (Estimate\u2009=\u20095.03,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02) symptom scores were found in the active versus sham group. Active rTMS also improved attention (Estimate\u2009=\u20096.58,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), and suppressed increased tobacco use that was associated with cannabis reductions (Treatment x Time:\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01). Our preliminary findings suggest that rTMS to the DLPFC is safe and potentially efficacious for treating CUD in schizophrenia.\n                  <\/jats:p>","DOI":"10.1038\/s41537-022-00210-6","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T15:57:05Z","timestamp":1647446225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia"],"prefix":"10.1038","volume":"8","author":[{"given":"Karolina Kozak","family":"Bidzinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darby J. E.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9075-1761","authenticated-orcid":false,"given":"Marcos","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Sorkhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Blumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1645-9767","authenticated-orcid":false,"given":"Tony P.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"210_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson, F. J. et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 44, 1195\u20131203 (2018).","journal-title":"Schizophr Bull"},{"key":"210_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000497317","volume":"25","author":"I Menendez-Miranda","year":"2019","unstructured":"Menendez-Miranda, I. et al. History of lifetime cannabis use is associated with better cognition and worse real-world functioning in schizophrenia spectrum disorders. Eur. Addict. Res. 25, 111\u2013118 (2019).","journal-title":"Eur. Addict. Res."},{"key":"210_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/schbul\/sbp031","volume":"36","author":"J Koskinen","year":"2010","unstructured":"Koskinen, J., Lohonen, J., Koponen, H., Isohanni, M. & Miettunen, J. Rates of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 36, 1115\u20131124. (2010).","journal-title":"Schizophr Bull."},{"key":"210_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/npp.2017.198","volume":"43","author":"DS Hasin","year":"2018","unstructured":"Hasin, D. S. U.S. Epidemiology of Cannabis Use and Associated Problems. Neuropsychopharmacology 43, 195\u2013212 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"210_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt, G. E. et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug Alcohol Depend. 191, 234\u2013258 (2018).","journal-title":"Drug Alcohol Depend."},{"key":"210_CR6","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1017\/S0033291714000191","volume":"44","author":"E Manrique-Garcia","year":"2014","unstructured":"Manrique-Garcia, E. et al. Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol. Med. 44, 2513\u20132521 (2014).","journal-title":"Psychol. Med."},{"key":"210_CR7","doi-asserted-by":"crossref","unstructured":"Patel, R. et al. Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. Lancet 385, S79 (2015).","DOI":"10.1016\/S0140-6736(15)60394-4"},{"key":"210_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","volume":"57","author":"DC D\u2019Souza","year":"2005","unstructured":"D\u2019Souza, D. C. et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57, 594\u2013608 (2005).","journal-title":"Biol. Psychiatry"},{"key":"210_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(06)78001-1","volume":"78","author":"O Guillin","year":"2007","unstructured":"Guillin, O., Abi-Dargham, A. & Laruelle, M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 78, 1\u201339 (2007).","journal-title":"Int. Rev. Neurobiol."},{"key":"210_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1017\/S1092852920001479","volume":"26","author":"G Martinotti","year":"2021","unstructured":"Martinotti, G. et al. Substance-related exogenous psychosis: a postmodern syndrome. CNS Spectr. 26, 84\u201391 (2021).","journal-title":"CNS Spectr."},{"key":"210_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","volume":"6","author":"M Di Forti","year":"2019","unstructured":"Di Forti, M. et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 6, 427\u2013436 (2019).","journal-title":"Lancet Psychiatry"},{"key":"210_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/schbul\/sbt181","volume":"40","author":"M Di Forti","year":"2014","unstructured":"Di Forti, M. et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 40, 1509\u20131517 (2014).","journal-title":"Schizophr Bull."},{"key":"210_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/cpt.421","volume":"101","author":"RA Rabin","year":"2017","unstructured":"Rabin, R. A. & George, T. P. Understanding the link between cannabinoids and psychosis. Clin. Pharmacol. Therap. 101, 197\u2013199 (2017).","journal-title":"Clin. Pharmacol. Therap."},{"key":"210_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00406-002-0366-5","volume":"252","author":"G Bersani","year":"2002","unstructured":"Bersani, G. et al. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur. Arch. Psychiatry Clin. Neurosci. 252, 86\u201392 (2002).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"210_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.schres.2004.01.005","volume":"71","author":"MT Compton","year":"2004","unstructured":"Compton, M. T., Furman, A. C. & Kaslow, N. J. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr. Res. 71, 61\u201364 (2004).","journal-title":"Schizophr. Res."},{"key":"210_CR16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00213-014-3523-4","volume":"231","author":"MA Bloomfield","year":"2014","unstructured":"Bloomfield, M. A. et al. The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology (Berl) 231, 2251\u20132259 (2014).","journal-title":"Psychopharmacology (Berl)"},{"key":"210_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.schres.2011.02.017","volume":"128","author":"R Rabin","year":"2011","unstructured":"Rabin, R., Zakzanis, K. K. & George, T. P. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr. Res. 128, 111\u2013116 (2011).","journal-title":"Schizophr. Res."},{"key":"210_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","volume":"57","author":"D D\u2019Souza","year":"2005","unstructured":"D\u2019Souza, D. et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57, 594\u2013608 (2005).","journal-title":"Biol. Psychiatry"},{"key":"210_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/npp.2017.85","volume":"42","author":"RA Rabin","year":"2017","unstructured":"Rabin, R. A. et al. Effects of extended cannabis abstinence on neurocognitive outcomes in cannabis dependent schizophrenia patients versus non-psychiatric controls. Neuropsychopharmacology 42, 2259\u20132271 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"210_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","volume":"26","author":"MF Green","year":"2000","unstructured":"Green, M. F. et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u201cright stuff\u201d? Schizophr Bull. 26, 119\u2013136 (2000).","journal-title":"Schizophr Bull"},{"key":"210_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s11920-996-0037-8","volume":"3","author":"RE Drake","year":"2001","unstructured":"Drake, R. E. & Mueser, K. T. Managing comorbid schizophrenia and substance abuse. Curr. Psychiatry Rep. 3, 418\u2013422 (2001).","journal-title":"Curr. Psychiatry Rep."},{"key":"210_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0920-9964(02)00231-1","volume":"60","author":"AI Green","year":"2003","unstructured":"Green, A. I. et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr. Res. 60, 81\u201385 (2003).","journal-title":"Schizophr. Res"},{"key":"210_CR23","first-page":"51","volume":"26","author":"SM Tang","year":"2017","unstructured":"Tang, S. M., Ansarian, A. & Courtney, D. B. Clozapine treatment and cannabis use in adolescents with psychotic disorders\u2014 a retrospective cohort chart review. J. Can. Acad. Child Adolesc. Psychiatry 26, 51\u201358 (2017).","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"210_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/15504263.2011.570118","volume":"7","author":"MF Brunette","year":"2011","unstructured":"Brunette, M. F. et al. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J. Dual Diagn. 7, 50\u201363 (2011).","journal-title":"J. Dual Diagn."},{"key":"210_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1521-0391.2014.12126.x","volume":"23","author":"T Schnell","year":"2014","unstructured":"Schnell, T. et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am. J. Addict. 23, 308\u2013312 (2014).","journal-title":"Am. J. Addict."},{"key":"210_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s40501-015-0043-8","volume":"2","author":"BR Schultz","year":"2015","unstructured":"Schultz, B. R. et al. Treatment strategies for cannabis use in schizophrenia. Curr. Treatment Options Psychiatry 2, 168\u2013181 (2015).","journal-title":"Curr. Treatment Options Psychiatry"},{"key":"210_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.addbeh.2009.02.001","volume":"34","author":"C Hjorthoj","year":"2009","unstructured":"Hjorthoj, C., Fohlmann, A. & Nordentoft, M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review. Addict. Behav. 34, 520\u2013525 (2009).","journal-title":"Addict. Behav."},{"key":"210_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.schres.2017.05.006","volume":"194","author":"RA Rabin","year":"2018","unstructured":"Rabin, R. A. et al. A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. Schizophr. Res. 194, 47\u201354 (2018).","journal-title":"Schizophr. Res."},{"key":"210_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/ajad.12674","volume":"27","author":"AS Coles","year":"2018","unstructured":"Coles, A. S., Kozak, K. & George, T. P. A review of brain stimulation for treatment of substance use disorders. Am. J. Addict. 27, 71\u201391 (2018).","journal-title":"Am. J. Addict."},{"key":"210_CR30","doi-asserted-by":"publisher","first-page":"117149","DOI":"10.1016\/j.jns.2020.117149","volume":"418","author":"JJ Mahoney 3rd","year":"2020","unstructured":"Mahoney, J. J. 3rd et al. Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment. J. Neurol. Sci. 418, 117149 (2020).","journal-title":"J. Neurol. Sci"},{"key":"210_CR31","doi-asserted-by":"publisher","first-page":"815215","DOI":"10.1155\/2014\/815215","volume":"2014","author":"E Bellamoli","year":"2014","unstructured":"Bellamoli, E. et al. rTMS in the treatment of drug addiction: an update about human studies. Behav. Neurol. 2014, 815215 (2014).","journal-title":"Behav. Neurol."},{"key":"210_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/nyas.12985","volume":"1394","author":"K Dunlop","year":"2017","unstructured":"Dunlop, K., Hanlon, C. A. & Downar, J. Noninvasive brain stimulation treatments for addiction and major depression. Ann. N Y Acad. Sci. 1394, 31\u201354 (2017).","journal-title":"Ann. N Y Acad. Sci."},{"key":"210_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrn.2017.113","volume":"18","author":"M Diana","year":"2017","unstructured":"Diana, M. et al. Rehabilitating the addicted brain with transcranial magnetic stimulation. Nat. Rev. Neurosci. 18, 685\u2013693 (2017).","journal-title":"Nat. Rev. Neurosci"},{"key":"210_CR34","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/add.14753","volume":"114","author":"JJQ Zhang","year":"2019","unstructured":"Zhang, J. J. Q. et al. Effects of repetitive transcranial magnetic stimulation (rTMS) on craving and substance consumption in patients with substance dependence: a systematic review and meta-analysis. Addiction 114, 2137\u20132149 (2019).","journal-title":"Addiction"},{"key":"210_CR35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.neubiorev.2009.11.006","volume":"34","author":"J Feil","year":"2010","unstructured":"Feil, J. & Zangen, A. Brain stimulation in the study and treatment of addiction. Neurosci. Biobehav. Rev. 34, 559\u2013574 (2010).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"210_CR36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/nyas.12479","volume":"1327","author":"DA Gorelick","year":"2014","unstructured":"Gorelick, D. A., Zangen, A. & George, M. S. Transcranial magnetic stimulation in the treatment of substance addiction. Ann. N Y Acad. Sci. 1327, 79\u201393 (2014).","journal-title":"Ann. N Y Acad. Sci."},{"key":"210_CR37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1124\/pr.116.013649","volume":"70","author":"CA Hanlon","year":"2018","unstructured":"Hanlon, C. A., Dowdle, L. T. & Henderson, J. S. Modulating neural circuits with transcranial magnetic stimulation: implications for addiction treatment development. Pharmacol. Rev. 70, 661\u2013683 (2018).","journal-title":"Pharmacol. Rev."},{"key":"210_CR38","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1038\/npp.2016.80","volume":"41","author":"MC Salling","year":"2016","unstructured":"Salling, M. C. & Martinez, D. Brain stimulation in addiction. Neuropsychopharmacology 41, 2798\u20132809 (2016).","journal-title":"Neuropsychopharmacology"},{"key":"210_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fnins.2020.00137","volume":"14","author":"J Moretti","year":"2020","unstructured":"Moretti, J., Poh, E. Z. & Rodger, J. rTMS-Induced changes in glutamatergic and dopaminergic systems: relevance to cocaine and methamphetamine use disorders. Front. Neurosci. 14, 137 (2020).","journal-title":"Front. Neurosci."},{"key":"210_CR40","first-page":"10","volume":"17","author":"T Ikeda","year":"2019","unstructured":"Ikeda, T., Kobayashi, S. & Morimoto, C. Effects of repetitive transcranial magnetic stimulation on ER stress-related genes and glutamate, gamma-aminobutyric acid and glycine transporter genes in mouse brain. Biochem. Biophys. Rep. 17, 10\u201316 (2019).","journal-title":"Biochem. Biophys. Rep."},{"key":"210_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/00952990.2017.1355920","volume":"44","author":"GL Sahlem","year":"2018","unstructured":"Sahlem, G. L. et al. Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users. Am. J. Drug Alcohol Abuse 44, 47\u201355 (2018).","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"210_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.brs.2019.09.014","volume":"13","author":"GL Sahlem","year":"2020","unstructured":"Sahlem, G. L. et al. A case series exploring the effect of twenty sessions of repetitive transcranial magnetic stimulation (rTMS) on cannabis use and craving. Brain Stimul. 13, 265\u2013266 (2020).","journal-title":"Brain Stimul"},{"key":"210_CR43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12264-017-0185-3","volume":"33","author":"Q Guo","year":"2017","unstructured":"Guo, Q., Li, C. & Wang, J. Updated Review on the Clinical Use of Repetitive Transcranial Magnetic Stimulation in Psychiatric Disorders. Neurosci. Bull. 33, 747\u2013756 (2017).","journal-title":"Neurosci. Bull."},{"key":"210_CR44","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.schres.2012.03.006","volume":"139","author":"VC Wing","year":"2012","unstructured":"Wing, V. C. et al. High-frequency repetitive transcranial magnetic stimulation (rTMS) reduces tobacco craving in smokers with schizophrenia. Schizophr. Res. 139, 264\u2013266 (2012).","journal-title":"Schizophr. Res."},{"key":"210_CR45","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.schres.2018.02.015","volume":"197","author":"K Kozak","year":"2018","unstructured":"Kozak, K. et al. Effects of short-term, high-frequency repetitive transcranial magnetic stimulation to bilateral dorsolateral prefrontal cortex on smoking behavior and cognition in patients with schizophrenia and non-psychiatric controls. Schizophr. Res. 197, 441\u2013443 (2018).","journal-title":"Schizophr. Res."},{"key":"210_CR46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/2229-3485.83221","volume":"2","author":"SK Gupta","year":"2011","unstructured":"Gupta, S. K. Intention-to-treat concept: A review. Perspect. Clin. Res. 2, 109\u2013112 (2011).","journal-title":"Perspect. Clin. Res."},{"key":"210_CR47","unstructured":"Trites, R. Instruction manual for the 23025 Grooved Pegboard Test. Lafayette Instrument Company (1989)."},{"key":"210_CR48","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1046\/j.1360-0443.2001.967102312.x","volume":"96","author":"SJ Heishman","year":"2001","unstructured":"Heishman, S. J., Singleton, E. G. & Liguori, A. Marijuana craving questionnaire: development and initial validation of a self-report instrument. Addiction 96, 1023\u20131034 (2001).","journal-title":"Addiction"},{"key":"210_CR49","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1126\/science.275.5306.1593","volume":"275","author":"W Schultz","year":"1997","unstructured":"Schultz, W., Dayan & Montague, P. R. A neural substrate of prediction and reward. Science 275, 1593\u20131599 (1997).","journal-title":"Science"},{"key":"210_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2017.03.010","volume":"194","author":"RA Rabin","year":"2018","unstructured":"Rabin, R. A. et al. Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophr. Res. 194, 55\u201361 (2018).","journal-title":"Schizophr. Res."},{"key":"210_CR51","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1388-2457(01)00585-5","volume":"112","author":"EM Wassermann","year":"2001","unstructured":"Wassermann, E. M. & Lisanby, S. H. Therapeutic application of repetitive transcranial magnetic stimulation: a review. Clin Neurophysiol. 112, 1367\u20131377 (2001).","journal-title":"Clin Neurophysiol"},{"key":"210_CR52","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1017\/S0033291704002338","volume":"34","author":"G Hajak","year":"2004","unstructured":"Hajak, G. et al. High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychol. Med. 34, 1157\u20131163 (2004).","journal-title":"Psychol. Med."},{"key":"210_CR53","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4088\/JCP.v68n0310","volume":"68","author":"A Aleman","year":"2007","unstructured":"Aleman, A., Sommer, I. E. & Kahn, R. S. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. J. Clin. Psychiatry 68, 416\u2013421 (2007).","journal-title":"J. Clin. Psychiatry"},{"key":"210_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.schres.2008.11.027","volume":"108","author":"C Freitas","year":"2009","unstructured":"Freitas, C., Fregni, F. & Pascual-Leone, A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr. Res. 108, 11\u201324 (2009).","journal-title":"Schizophr. Res."},{"key":"210_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/YCT.0b013e3181f41ea3","volume":"27","author":"AD Stanford","year":"2011","unstructured":"Stanford, A. D. et al. High-frequency prefrontal repetitive transcranial magnetic stimulation for the negative symptoms of schizophrenia: a case series. J. ECT 27, 11\u20137 (2011).","journal-title":"J. ECT"},{"key":"210_CR56","doi-asserted-by":"publisher","first-page":"401A","DOI":"10.1097\/00002826-199201001-00209","volume":"15","author":"PF Liddle","year":"1992","unstructured":"Liddle, P. F. Regional brain abnormalities associated with specific syndromes of persistent schizophrenic symptoms. Clin. Neuropharmacol. 15, 401A\u2013402A (1992).","journal-title":"Clin. Neuropharmacol"},{"key":"210_CR57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fphar.2012.00195","volume":"3","author":"TL Schwartz","year":"2012","unstructured":"Schwartz, T. L., Sachdeva, S. & Stahl, S. M. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front. Pharmacol. 3, 195 (2012).","journal-title":"Front. Pharmacol."},{"key":"210_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jpsychires.2014.01.004","volume":"51","author":"HN Wang","year":"2014","unstructured":"Wang, H. N. et al. Anti-depressive mechanism of repetitive transcranial magnetic stimulation in rat: the role of the endocannabinoid system. J. Psychiatr. Res. 51, 79\u201387 (2014).","journal-title":"J. Psychiatr. Res."},{"key":"210_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2017.04.033","volume":"124","author":"DP Covey","year":"2017","unstructured":"Covey, D. P. et al. Endocannabinoid modulation of dopamine neurotransmission. Neuropharmacology 124, 52\u201361 (2017).","journal-title":"Neuropharmacology"},{"key":"210_CR60","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.biopsych.2015.08.021","volume":"79","author":"M Ranganathan","year":"2016","unstructured":"Ranganathan, M. et al. Reduced brain cannabinoid receptor availability in schizophrenia. Biol. Psychiatry. 79, 997\u20131005 (2016).","journal-title":"Biol. Psychiatry."},{"key":"210_CR61","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1162\/jocn_a_00358","volume":"25","author":"A Olsen","year":"2013","unstructured":"Olsen, A. et al. The functional topography and temporal dynamics of overlapping and distinct brain activations for adaptive task control and stable task-set maintenance during performance of an fMRI-adapted clinical continuous performance test. J. Cogn. Neurosci. 25, 903\u2013919 (2013).","journal-title":"J. Cogn. Neurosci."},{"key":"210_CR62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hbm.22169","volume":"35","author":"YH Wu","year":"2014","unstructured":"Wu, Y. H. et al. White matter tract integrity of frontostriatal circuit in attention deficit hyperactivity disorder: association with attention performance and symptoms. Hum. Brain Mapp. 35, 199\u2013212 (2014).","journal-title":"Hum. Brain Mapp."},{"key":"210_CR63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/ajad.12186","volume":"24","author":"R Rabin","year":"2015","unstructured":"Rabin, R. & George, T. P. A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. Am. J. Addict. 24, 105\u2013116 (2015).","journal-title":"Am. J. Addict."},{"key":"210_CR64","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1521-0391.2013.12084.x","volume":"23","author":"RA Rabin","year":"2014","unstructured":"Rabin, R. A., Giddens, J. L. & George, T. P. Relationship between tobacco and cannabis use status in outpatients with schizophrenia. Am. J. Addict. 23, 170\u2013175 (2014).","journal-title":"Am. J. Addict."},{"key":"210_CR65","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.drugalcdep.2017.12.017","volume":"185","author":"RA Rabin","year":"2018","unstructured":"Rabin, R. A., Dermody, S. S. & George, T. P. Changes in tobacco consumption in cannabis dependent patients with schizophrenia versus non-psychiatric controls during 28-days of cannabis abstinence. Drug Alcohol Depend. 185, 181\u2013188 (2018c).","journal-title":"Drug Alcohol Depend."},{"key":"210_CR66","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1360-0443.2010.03228.x","volume":"106","author":"EW Schwilke","year":"2011","unstructured":"Schwilke, E. W. et al. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction 106, 499\u2013506 (2011).","journal-title":"Addiction"},{"key":"210_CR67","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/jat\/bkab037","volume":"45","author":"T Breindahl","year":"2021","unstructured":"Breindahl, T. et al. Implementation of mathematical models to predict new cannabis use by urine drug testing: it is time to move forward. J. Anal. Toxicol. 45, e15\u2013e19 (2021).","journal-title":"J. Anal. Toxicol."},{"key":"210_CR68","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261\u2013276 (1987).","journal-title":"Schizophr. Bull."},{"key":"210_CR69","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.drugalcdep.2010.02.017","volume":"110","author":"SJ Adamson","year":"2010","unstructured":"Adamson, S. J. et al. An improved brief measure of cannabis misuse: the cannabis use disorders identification test-revised (CUDIT-R). Drug Alcohol Depend. 110, 137\u2013143 (2010).","journal-title":"Drug Alcohol Depend."},{"key":"210_CR70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2005.10.007","volume":"83","author":"JD Slavet","year":"2006","unstructured":"Slavet, J. D. et al. The Marijuana Ladder: measuring motivation to change marijuana use in incarcerated adolescents. Drug Alcohol Depend. 83, 42\u201348 (2006).","journal-title":"Drug Alcohol Depend."},{"key":"210_CR71","unstructured":"Wechsler, D. Wechsler Test of Adult Reading (WTAR) (The Psychological Corporation, San Antonio, TX, 2001)."},{"key":"210_CR72","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner, K. et al. The columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 168, 1266\u20131277 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"210_CR73","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton, T. F. et al. The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. Br. J. Addict. 86, 1119\u20131127 (1991).","journal-title":"Br. J. Addict"},{"key":"210_CR74","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.psychres.2012.11.019","volume":"206","author":"RA Rabin","year":"2013","unstructured":"Rabin, R. A. et al. Effects of cannabis use status on cognitive function, in males with schizophrenia. Psychiatry Res. 206, 158\u2013165 (2013).","journal-title":"Psychiatry Res."},{"key":"210_CR75","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","volume":"88","author":"JB Saunders","year":"1993","unstructured":"Saunders, J. B. et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 88, 791\u2013804 (1993).","journal-title":"Addiction"},{"key":"210_CR76","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1046\/j.1360-0443.1999.94913114.x","volume":"94","author":"AJ Budney","year":"1999","unstructured":"Budney, A. J., Novy, P. L. & Hughes, J. R. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94, 1311\u20131322 (1999).","journal-title":"Addiction"},{"key":"210_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.drugalcdep.2008.12.010","volume":"102","author":"SJ Heishman","year":"2009","unstructured":"Heishman, S. J. et al. Reliability and validity of a short form of the marijuana craving questionnaire. Drug Alcohol Depend. 102, 35\u201340 (2009).","journal-title":"Drug Alcohol Depend."},{"key":"210_CR78","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0306-4603(96)00039-1","volume":"21","author":"LC Sobell","year":"1996","unstructured":"Sobell, L. C. et al. Fostering self-change among problem drinkers: a proactive community intervention. Addict. Behav. 21, 817\u2013833 (1996).","journal-title":"Addict. Behav."},{"key":"210_CR79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/CXA.0000000000000090","volume":"3","author":"AM Lucatch","year":"2020","unstructured":"Lucatch, A. M., Klober, S., Rizvi, S., Meyer, J. M. & George, T. P. Effects of cannabis abstinence on clinical outcomes in people with cannabis use disorder and major depression. Can. J. Addict. 3, 33\u201341 (2020).","journal-title":"Can. J. Addict."},{"key":"210_CR80","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1192\/S0007125000292581","volume":"22","author":"D Addington","year":"1993","unstructured":"Addington, D., Addington, J. & Maticka-Tyndale, E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 22, 39\u201344 (1993).","journal-title":"Br. J. Psychiatry Suppl."},{"key":"210_CR81","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1037\/0022-006X.68.6.1051","volume":"68","author":"AJ Budney","year":"2000","unstructured":"Budney, A. J. et al. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J. Consult Clin. Psychol. 68, 1051\u20131061 (2000).","journal-title":"J. Consult Clin. Psychol."},{"key":"210_CR82","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1098\/rstb.1982.0082","volume":"298","author":"T Shallice","year":"1982","unstructured":"Shallice, T. Specific impairments of planning. Philos. Trans. R Soc. Lond B Biol. Sci. 298, 199\u2013209 (1982).","journal-title":"Philos. Trans. R Soc. Lond B Biol. Sci."},{"key":"210_CR83","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.biopsych.2013.07.038","volume":"75","author":"VB Perez","year":"2014","unstructured":"Perez, V. B. et al. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol. Psychiatry. 75, 459\u2013469 (2014).","journal-title":"Biol. Psychiatry."},{"key":"210_CR84","doi-asserted-by":"crossref","unstructured":"Jarkiewicz, M. & Wichniak, A. Can new paradigms bring new perspectives for mismatch negativity studies in schizophrenia? Neuropsychiatr. Electrophysiol. 1, 12 (2015).","DOI":"10.1186\/s40810-015-0010-z"},{"key":"210_CR85","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/hbm.20964","volume":"31","author":"PM Rusjan","year":"2010","unstructured":"Rusjan, P. M. et al. Optimal transcranial magnetic stimulation coil placement for targeting the dorsolateral prefrontal cortex using novel magnetic resonance image-guided neuronavigation. Hum. Brain Mapp. 31, 1643\u20131652 (2010).","journal-title":"Hum. Brain Mapp."},{"key":"210_CR86","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/cercor\/bht023","volume":"24","author":"L Cardenas-Morales","year":"2013","unstructured":"Cardenas-Morales, L. et al. Network connectivity and individual responses to brain stimulation in the human motor system. Cereb. Cortex 24, 1697\u20131707 (2013).","journal-title":"Cereb. Cortex"},{"key":"210_CR87","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","volume":"317","author":"JM Bland","year":"1998","unstructured":"Bland, J. M. & Altman, D. G. Survival probabilities (the Kaplan-Meier method). BMJ 317, 1572 (1998).","journal-title":"BMJ"}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-022-00210-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-022-00210-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-022-00210-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T17:39:05Z","timestamp":1700329145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-022-00210-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["210"],"URL":"https:\/\/doi.org\/10.1038\/s41537-022-00210-6","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. George has received honoraria from Frutarom, Novartis, the Canadian Centre for Substance Use and Addiction (CCSA) and The American College of Neuropsychopharmacology (ACNP). Dr. Blumberger received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he is the site principal investigator for one sponsor-initiated study for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies, and medication supplies for an investigator-initiated trial from Indivior.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}